The Texas Pharmaceutical Manufacturing Expansion
Texas has emerged as one of the most active states for pharmaceutical and biotech manufacturing investment in the post-pandemic era. The combination of a large skilled labor pool, competitive real estate costs relative to New Jersey and California, strong logistics infrastructure, and a business-friendly regulatory environment has attracted significant capital to Texas pharmaceutical manufacturing.
The growth is across multiple segments: biosimilar manufacturing facilities in the Austin corridor, compounding pharmacies scaling to commercial-grade production in Houston, API (active pharmaceutical ingredient) production facilities near the Gulf Coast chemical complex, nutraceutical and supplement manufacturing across DFW, and contract development and manufacturing organizations (CDMOs) establishing Texas operations to serve regional pharmaceutical clients.
What most of this growth has in common: the facilities require GMP construction — and most Texas industrial contractors do not know how to deliver it.
What FDA cGMP Actually Requires for Construction
The FDA's Current Good Manufacturing Practice regulations for pharmaceuticals are codified in 21 CFR Part 211 (finished pharmaceuticals) and related regulations for API (21 CFR Part 211 and ICH Q7). These regulations do not specify construction methods in detail — they specify outcomes, and your facility must demonstrate it can achieve and maintain those outcomes.
Key regulatory outcomes that drive construction decisions:
Facilities must be designed to facilitate cleaning. Surfaces that contact pharmaceutical products — walls, floors, ceilings, equipment supports — must be smooth, non-reactive, non-additive, and cleanable. This drives material selection away from exposed concrete, rough masonry, and standard drywall toward specialized pharmaceutical-grade surfaces.
Separation of operations that could cause contamination. Manufacturing areas must be physically separated from each other, from testing labs, and from non-manufacturing areas to prevent cross-contamination. This drives floor plan layout decisions and determines where airlocks, pressure differentials, and dedicated HVAC zones are required.
Controlled environmental conditions. Temperature, humidity, and particulate levels must be controlled and documented during manufacturing. This drives HVAC design toward redundant, validated systems rather than standard commercial HVAC.
Documentation of construction activities. During construction, validation activities begin. The owner's quality team typically conducts Installation Qualification (IQ) activities concurrent with construction — verifying that installed systems meet the design specification. This requires the contractor to provide specific documentation, inspection access, and coordination that standard industrial construction does not involve.
The takeaway: GMP construction is not just about building a clean building. It is about building a system that can be validated — documented proof that it was built right, operates as designed, and produces pharmaceutical-grade outcomes consistently.
Cleanroom Classifications and What Drives Them
ISO cleanroom classifications (replacing the old Fed-Std-209E Class system) define the maximum allowable particle count in the air at a given particle size. ISO 5 (equivalent to old Class 100) is the most demanding; ISO 8 (equivalent to old Class 100,000) is the least demanding of the pharmaceutical-grade classifications.
What drives the required classification:
ISO 5 (Class 100): Required for aseptic filling operations where sterile drug products are exposed to the environment. Typically a very small footprint within a larger cleanroom suite. Positive pressure relative to adjacent spaces. 100% HEPA-filtered supply air with multiple air changes per hour (typically 300-600 ACPH). Unidirectional (laminar) airflow at filling stations.
ISO 7 (Class 10,000): Required for preparation areas adjacent to ISO 5 filling. HEPA filtration, 60-90 ACPH, positive pressure differential maintained. Used in sterile manufacturing support areas.
ISO 8 (Class 100,000): Appropriate for most non-sterile pharmaceutical manufacturing areas — oral solid dosage (tablets and capsules), topical preparations, most compounding operations. 20-60 ACPH. HEPA or HEPA-bank supply air. Still requires significant HVAC investment compared to standard industrial.
Controlled but unclassified areas: Packaging, labeling, warehousing of finished products. Standard HVAC with temperature and humidity control; no air classification required but still subject to GMP cleanliness standards.
The design of your facility starts with a room classification matrix — defining what classification applies to each space based on the operations performed there. This classification matrix drives everything else: HVAC design, surface specifications, cleaning procedures, personnel flow, and material flow.
HVAC Design for Pharmaceutical: The Most Consequential System
On a pharmaceutical facility, HVAC is not background infrastructure — it is a primary process system. Getting it right requires a mechanical engineer with genuine pharmaceutical HVAC experience, not a commercial or standard industrial MEP engineer.
Air handling unit design. Pharmaceutical AHUs are not standard commercial units. They typically include 100% outside air capability (for purge cycles), high-efficiency filtration banks (MERV-14 pre-filters plus HEPA final filters), stainless steel or coated interior surfaces for cleanability, tight control of leaving air conditions (temperature and relative humidity within ±1-2% of setpoint), and validation ports for instrumentation access.
Redundancy. A pharmaceutical facility cannot simply lose HVAC and shut down — that would compromise in-process product and require significant revalidation effort. Critical manufacturing areas require N+1 redundancy on AHUs and, in some cases, on major mechanical components.
Pressure cascade design. Manufacturing areas must maintain defined pressure differentials relative to adjacent spaces to control contamination flow direction. The design creates a pressure cascade: the cleanest areas are at highest positive pressure, and pressure decreases as you move toward less clean areas. Potent compound operations may flip this — keeping potent areas at negative pressure to prevent release of hazardous compounds to surrounding spaces.
HEPA terminal filtration. In classified areas, HEPA filters are installed at the terminal supply air devices (diffusers or HEPA filter/fan units). These filters achieve 99.97% efficiency at 0.3 microns. They require periodic leak testing (IEST RP-CC034) and replacement, so access and clearances must be designed in from the start.
Humidity control. Many pharmaceutical manufacturing processes are moisture-sensitive. Oral solid dosage operations typically require 45-55% relative humidity ±5%. Maintaining this in a Texas summer — when ambient humidity can be 80%+ — requires robust chilled water cooling capacity and precise humidity control logic in the building automation system.
Validated control systems. The HVAC control system (BAS) must be qualified as part of the validation process. This means the controls contractor must provide comprehensive documentation, the system must be calibrated with traceable standards, and alarms must be configured and tested. Plan for 60-90 days of commissioning and validation activities after mechanical completion.
Flooring for Pharmaceutical Facilities
Flooring selection in pharmaceutical is not aesthetic — it is functional and regulatory. The floor must be cleanable, seamless or minimally-jointed, non-reactive with cleaning agents and pharmaceutical materials, and durable against equipment loads and cleaning chemical exposure.
Broadcast epoxy with cove base. The most common pharmaceutical floor system in Texas facilities. 100% solids epoxy, typically 3-5 mm thick, applied over prepared concrete. Self-leveling formulations create a smooth surface. The critical detail is the cove base — a concave transition between floor and wall, typically 4 inches high — that eliminates the 90-degree corner where contamination accumulates. Cove base must be continuous with no gaps or cracks. Well-installed broadcast epoxy: $8-15/SF installed.
Urethane concrete (polyurethane cement). Better chemical resistance and thermal shock resistance than epoxy — important in areas with wet cleaning, steam cleaning, or temperature variation. More expensive ($15-25/SF) but preferred in processing areas with aggressive cleaning protocols.
Polished concrete. Increasingly used in warehouse and secondary manufacturing areas with less stringent contamination requirements. Polished to a specific grit level (typically 1,500-3,000 grit for pharmaceutical), densified with lithium silicate hardeners, and coated with penetrating sealer. Less expensive than epoxy but provides a harder, more impact-resistant surface.
Tile (epoxy grout). Some clients specify pharmaceutical-grade floor tile with narrow-joint epoxy grout in primary manufacturing areas. This provides excellent chemical resistance but requires extremely careful grout installation — any voids or thin spots in grout joints create contamination harboring points and will fail an FDA inspection.
Regardless of system selected: prepare the concrete sub-floor properly. Shot-blasting to ICRI Concrete Surface Profile 3-4 is standard. Moisture vapor emission rates must be within system requirements — a common failure point on Texas sites where ground moisture is high. Address slab moisture before applying any flooring system.
Wall and Ceiling Systems for Pharmaceutical
The same cleanability principle that drives flooring selection applies to walls and ceilings.
Standard drywall is not acceptable in classified manufacturing areas. Drywall seams telegraph, seams and fastener heads can harbor contamination, and the surface is damaged by cleaning chemicals over time.
Impact-resistant gypsum (abuse-resistant drywall): An upgrade from standard drywall with fiberglass or reinforced core, but still a drywall product. Appropriate in lower-classification areas (ISO 8, controlled but unclassified) with lighter cleaning requirements. Must be skim-coated, sealed, and painted with semi-gloss or high-gloss epoxy paint for pharmaceutical use.
Modular cleanroom wall panels: PVC or aluminum-framed panels with smooth, cleanable facing materials (typically aluminum composite, HDPE, or fiberglass-reinforced plastic). Panel joints are sealed with pharmaceutical-grade silicone. No exposed fasteners. This is the preferred system for ISO 7 and ISO 5 areas and is also widely used in ISO 8. Panel systems are more expensive upfront ($35-65/SF installed) but provide better long-term performance and are easier to reconfigure.
Flush hardware requirement: Electrical outlets, switches, data ports, and HVAC returns in classified areas must be flush-mounted with no exposed gaps, ledges, or cavities. Recessed light fixtures must be gasketed and sealed. Every penetration through a wall or ceiling must be sealed with pharmaceutical-grade sealant. Inspectors from FDA look at penetrations closely — an unsealed electrical conduit penetration is a citation.
Ceiling systems: Lay-in tile ceilings are not appropriate in classified areas. Options include hard-lid gypsum ceilings (sealed and painted), modular panel ceiling systems that match the wall system, or cleanroom ceiling grid systems with HEPA terminal filtration units integrated. Whichever system is used, all light fixtures must be sealed and all penetrations must be gasketed and caulked.
Documentation During Construction: The IQ/OQ Process
Pharmaceutical facility construction is distinguished from standard construction by the validation documentation process that runs concurrently.
Installation Qualification (IQ): Documents that installed systems match the approved design specification. Examples: the installed AHU has the specified filtration, the installed HEPA filters are the approved model and rating, the installed controls are calibrated. IQ requires the contractor to provide equipment submittals, installation records, and inspection access at each phase of construction.
Operational Qualification (OQ): Documents that installed systems operate as designed when tested. Examples: the HVAC system achieves and maintains specified temperature and humidity setpoints across operating conditions, pressure differentials are correct in all defined scenarios, airflow volumes at each supply device meet specification. OQ testing occurs after commissioning, typically 30-60 days before substantial completion.
Performance Qualification (PQ): Documents that the completed facility consistently produces the required environmental conditions during actual manufacturing operations. PQ occurs after occupancy, using actual manufacturing equipment running actual (or simulated) pharmaceutical processes.
The contractor's role in qualification: provide documentation, provide inspection access, correct deficiencies identified during IQ/OQ, and coordinate with the owner's validation team. Contractors unfamiliar with this process resist the documentation burden, push back on access requirements, and create friction with the validation timeline.
Ask any contractor bidding your pharmaceutical project: "Have you supported IQ/OQ on a pharmaceutical facility? Can you give us a reference contact at the owner's QA team?" If they look blank, keep looking.
Texas Pharma Market Drivers: Why Now
Several converging factors are driving Texas pharmaceutical manufacturing investment:
Biosimilar manufacturing: The patent cliff on major biologics is driving biosimilar production investment. Texas benefits from proximity to large patient populations and established biotech in Austin and Houston. UT Southwestern, MD Anderson, and the Texas Medical Center create pharmaceutical talent that manufacturing companies can recruit.
Compounding pharmacy growth: Large-scale 503B outsourcing facility compounding (GMP-compliant compounding for healthcare organizations) has grown dramatically. Texas's large healthcare market and multiple major health systems (HCA, CHRISTUS, Baylor Scott & White) create demand that Texas 503B operators are positioned to serve.
Supplement and nutraceutical manufacturing: Texas's position as a large consumer market and logistics hub makes it attractive for dietary supplement manufacturers. NSF GMP certification (different from FDA GMP but similar principles) is common in this segment.
API production: The COVID-19 pandemic revealed extreme US dependence on Asian API production. Federal investment incentives and supply chain diversification pressure have driven domestic API manufacturing investment. Gulf Coast Texas, with its existing chemical manufacturing infrastructure and workforce, is a natural location for API production facilities.
What to Look for in a Texas GMP Contractor
A contractor who can deliver GMP pharmaceutical facilities competently will be able to demonstrate:
Previous pharmaceutical or regulated industry project experience with reference contacts at owner's QA team, not just the project owner, Familiarity with cleanroom standards (ISO 14644) and HVAC guidelines (ISPE Baseline Guides), A quality management system with RFI and submittal processes that support validation documentation, Relationships with pharmaceutical-grade specialty subcontractors: cleanroom wall panel installers, pharmaceutical flooring contractors, controls contractors with pharmaceutical SCADA experience, and Willingness to support IQ/OQ without treating it as an out-of-scope add-on.
Standard industrial contractors without this background can build the shell, but will struggle on the MEP coordination, cleanroom envelope, and qualification documentation — which is where GMP facility projects succeed or fail.
Industrial Contractors of Texas has supported GMP facility construction including cleanroom systems, pharmaceutical HVAC, and qualification documentation across Texas markets.